Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer.
Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer.
复制标题
DOI:
10.1186/1471-2407-14-977
复制
发表时间:
2014-12-18
期刊:
影响因子:
3.8
通讯作者:
Leung HY
中科院分区:
文献类型:
--
作者:
Rajan P;Stockley J;Sudbery IM;Fleming JT;Hedley A;Kalna G;Sims D;Ponting CP;Heger A;Robson CN;McMenemin RM;Pedley ID;Leung HY
Although chemotherapy for prostate cancer (PCa) can improve patient survival, some tumours are chemo-resistant. Tumour molecular profiles may help identify the mechanisms of drug action and identify potential prognostic biomarkers. We performed in vivo transcriptome profiling of pre- and post-treatment prostatic biopsies from patients with advanced hormone-naive prostate cancer treated with docetaxel chemotherapy and androgen deprivation therapy (ADT) with an aim to identify the mechanisms of drug action and identify prognostic biomarkers. RNA sequencing (RNA-Seq) was performed on biopsies from four patients before and ~22 weeks after docetaxel and ADT initiation. Gene fusion products and differentially-regulated genes between treatment pairs were identified using TopHat and pathway enrichment analyses undertaken. Publically available datasets were interrogated to perform survival analyses on the gene signatures identified using cBioportal. A number of genomic rearrangements were identified including the TMPRSS2/ERG fusion and 3 novel gene fusions involving the ETS family of transcription factors in patients, both pre and post chemotherapy. In total, gene expression analyses showed differential expression of at least 2 fold in 575 genes in post-chemotherapy biopsies. Of these, pathway analyses identified a panel of 7 genes (ADAM7, FAM72B, BUB1B, CCNB1, CCNB2, TTK, CDK1), including a cell cycle-related geneset, that were differentially-regulated following treatment with docetaxel and ADT. Using cBioportal to interrogate the MSKCC-Prostate Oncogenome Project dataset we observed a statistically-significant reduction in disease-free survival of patients with tumours exhibiting alterations in gene expression of the above panel of 7 genes (p = 0.015). Here we report on the first “real-time” in vivo RNA-Seq-based transcriptome analysis of clinical PCa from pre- and post-treatment TRUSS-guided biopsies of patients treated with docetaxel chemotherapy plus ADT. We identify a chemotherapy-driven PCa transcriptome profile which includes the down-regulation of important positive regulators of cell cycle progression. A 7 gene signature biomarker panel has also been identified in high-risk prostate cancer patients to be of prognostic value. Future prospective study is warranted to evaluate the clinical value of this panel. The online version of this article (doi:10.1186/1471-2407-14-977) contains supplementary material, which is available to authorized users.
登录
查看更多内容
影响因子:
7.3
作者:
Gao J;Aksoy BA;Dogrusoz U;Dresdner G;Gross B;Sumer SO;Sun Y;Jacobsen A;Sinha R;Larsson E;Cerami E;Sander C;Schultz N
通讯作者:
Schultz N
影响因子:
23.4
作者:
Omlin, Aurelius;Pezaro, Carmel;de Bono, Johann
通讯作者:
de Bono, Johann
影响因子:
51.1
作者:
Gravis, Gwenaelle;Fizazi, Karim;Soulie, Michel
通讯作者:
Soulie, Michel
影响因子:
51.1
作者:
Cuzick, Jack;Swanson, Gregory P.;Fisher, Gabrielle;Brothman, Arthur R.;Berney, Daniel M.;Reid, Julia E.;Mesher, David;Speights, V. O.;Stankiewicz, Elzbieta;Foster, Christopher S.;Moller, Henrik;Scardino, Peter;Warren, Jorja D.;Park, Jimmy;Younus, Adib;Flake, Dart D., II;Wagner, Susanne;Gutin, Alexander;Lanchbury, Jerry S.;Stone, Steven
通讯作者:
Stone, Steven
影响因子:
158.5
作者:
Petrylak, DP;Tangen, CM;Crawford, ED
通讯作者:
Crawford, ED